Aecor Bio
Aecor.bio (formerly HBC Immunology) is a biotechnology company focused on developing AI-optimized peptide therapeutics to overcome treatment resistance across various diseases, particularly in oncology. Their unique approach involves using AI and proprietary algorithms to design and synthesize thousands of bioactive peptides through protein hydrolysis. These peptides are designed to target and reverse disrupted gene expression that causes treatment resistance, thereby repairing cellular micro-environments and restoring immune system function. Their lead candidate, FT-002a, is an orally administered peptide therapy aimed at normalizing iron metabolism and restoring sensitivity to chemotherapy in ovarian and prostate cancers. They are advancing FT-002a with an IND submission planned for Q4/2025.
Aecor Bio
Aecor.bio (formerly HBC Immunology) is a biotechnology company focused on developing AI-optimized peptide therapeutics to overcome treatment resistance across various diseases, particularly in oncology. Their unique approach involves using AI and proprietary algorithms to design and synthesize thousands of bioactive peptides through protein hydrolysis. These peptides are designed to target and reverse disrupted gene expression that causes treatment resistance, thereby repairing cellular micro-environments and restoring immune system function. Their lead candidate, FT-002a, is an orally administered peptide therapy aimed at normalizing iron metabolism and restoring sensitivity to chemotherapy in ovarian and prostate cancers. They are advancing FT-002a with an IND submission planned for Q4/2025.